[Objectives]To systematically evaluate the efficacy and safety of salmon calcitonin in the treatment of osteoporosis,and to provide reference for clinical salmon calcitonin treatment and improvement of bone pain sympt...[Objectives]To systematically evaluate the efficacy and safety of salmon calcitonin in the treatment of osteoporosis,and to provide reference for clinical salmon calcitonin treatment and improvement of bone pain symptoms of osteoporosis.[Methods]Randomized controlled trials(RCTs)of salmon calcitonin in the treatment of osteoporosis from January 2000 to March 2015 were collected by searching Chinese Biomechanics Literature Database(SinoMed,CBM),China National Knowledge Infrastructure(CNKI),VIP and Wanfang Database.The relevant data of bone pain degree and bone mineral density were extracted to evaluate the methodological quality.Meta-analysis was performed using RevMan 5.1 software.A total of 13 randomized controlled trials involving 1683 patients were included,including 862 patients in the observation group and 821 patients in the control group.[Results]Meta-analysis showed that salmon calcitonin combined with calcium was better than the control group in improving bone pain symptoms in osteoporosis patients,and the difference was statistically significant[RR=1.84,95%CI(1.56,2.18)].[Conclusions]The salmon calcitonin can significantly improve the bone pain symptoms of the osteoporosis patients,and has no serious adverse reaction.However,due to the small number of studies included in this systematic review and the small sample size,it still needs to be confirmed by high-quality,large sample,multi-center randomized controlled trials.展开更多
It was concluded that the described HPLC method could be used for the assayof salmon calcitonin in injection, as it offers qualified selectivity, accuracy and precision ofanalysis.
Secondary structure of [Val. Ala]sCT- an analog of salmon calcitonin (sCT) not containing an N-terminal disultide bridge. was investigated by circular dichroism (CD) and Fourier-transform intrared spectroscopy (FTIR) ...Secondary structure of [Val. Ala]sCT- an analog of salmon calcitonin (sCT) not containing an N-terminal disultide bridge. was investigated by circular dichroism (CD) and Fourier-transform intrared spectroscopy (FTIR) methods. Both CD and FTIR results show that the main contbrmational structure of [Val Ala']sCT in aqueous solution is random coil structure. while in trifluorethanol (TFE) it displays a strong α-helical structure. The relationship between the biological activity and the conformational structure of [Val, Ala] sCT is als0 discussed.展开更多
Peptide analogs of salmon calcitonin (sCT) were synthesized by using Fmoc-based chemistry on MBHA resins. Salmon calcitonin was modified by 1) cysteines at positions 1 and 7 were replaced by valine and alanine respect...Peptide analogs of salmon calcitonin (sCT) were synthesized by using Fmoc-based chemistry on MBHA resins. Salmon calcitonin was modified by 1) cysteines at positions 1 and 7 were replaced by valine and alanine respectively to result in open chain analogs, 2) the glycine at position 30 was replaced by alanine, D-alanine and sarcosine respectively, and 3) some residues were deleted besides the above two modifications. A modified two-step deprotection / cleavage procedure, in which a solvent of TFA / TMSBr / thioanisole / EDT / m-cresol combines with HF cleavage, was adopted in SPPS.展开更多
Osteoporosis is a disease of bone metabolism homeostasis imbalance with obvious bone loss,damage to bone microstructure,and increased risk of fracture.The occurrence and development of osteoporosis is related to the a...Osteoporosis is a disease of bone metabolism homeostasis imbalance with obvious bone loss,damage to bone microstructure,and increased risk of fracture.The occurrence and development of osteoporosis is related to the augmentation of active osteoclasts.Receptor activator of nuclear factor kappa B(RANK)small interfering RNA(siRNA)knockdowns the expression of RANK mRNA to inhibit the osteoclast precursors differentiate into osteoclasts as a treatment in osteoporosis.Salmon calcitonin(sCT)is a commonly used anti-osteoporotic agent that inhibits osteoclast activity and induces osteoclast apoptosis,and it also could promote the osteogenesis by osteoblasts.A cocktail therapy improves the therapeutic effect of osteoporosis between RANK siRNA and sCT.A size-switchable microsphere from micro to nano scale was developed to address the delivery barriers of biomacromolecules with poor stability and frequent administration.RANK siRNA and s CT were incorporated into the microspheres with a nanoparticle/micellemicrosphere double-layer structure to achieve sustained release when the particle size shrunk and dual protection of RANK siRNA and sCT.The size-switchable microspheres MS@(AL-NPs/ARM)had an optimal therapeutic effect and reduced the frequency of administration in glucocorticoid induced osteoporosis(GIOP)mouse model.RANK siRNA and s CT co-delivery system based on size-switchable microsphere is a promising strategy to treat osteoporosis through the controlled release of biomacromolecules.展开更多
文摘[Objectives]To systematically evaluate the efficacy and safety of salmon calcitonin in the treatment of osteoporosis,and to provide reference for clinical salmon calcitonin treatment and improvement of bone pain symptoms of osteoporosis.[Methods]Randomized controlled trials(RCTs)of salmon calcitonin in the treatment of osteoporosis from January 2000 to March 2015 were collected by searching Chinese Biomechanics Literature Database(SinoMed,CBM),China National Knowledge Infrastructure(CNKI),VIP and Wanfang Database.The relevant data of bone pain degree and bone mineral density were extracted to evaluate the methodological quality.Meta-analysis was performed using RevMan 5.1 software.A total of 13 randomized controlled trials involving 1683 patients were included,including 862 patients in the observation group and 821 patients in the control group.[Results]Meta-analysis showed that salmon calcitonin combined with calcium was better than the control group in improving bone pain symptoms in osteoporosis patients,and the difference was statistically significant[RR=1.84,95%CI(1.56,2.18)].[Conclusions]The salmon calcitonin can significantly improve the bone pain symptoms of the osteoporosis patients,and has no serious adverse reaction.However,due to the small number of studies included in this systematic review and the small sample size,it still needs to be confirmed by high-quality,large sample,multi-center randomized controlled trials.
文摘It was concluded that the described HPLC method could be used for the assayof salmon calcitonin in injection, as it offers qualified selectivity, accuracy and precision ofanalysis.
文摘Secondary structure of [Val. Ala]sCT- an analog of salmon calcitonin (sCT) not containing an N-terminal disultide bridge. was investigated by circular dichroism (CD) and Fourier-transform intrared spectroscopy (FTIR) methods. Both CD and FTIR results show that the main contbrmational structure of [Val Ala']sCT in aqueous solution is random coil structure. while in trifluorethanol (TFE) it displays a strong α-helical structure. The relationship between the biological activity and the conformational structure of [Val, Ala] sCT is als0 discussed.
文摘Peptide analogs of salmon calcitonin (sCT) were synthesized by using Fmoc-based chemistry on MBHA resins. Salmon calcitonin was modified by 1) cysteines at positions 1 and 7 were replaced by valine and alanine respectively to result in open chain analogs, 2) the glycine at position 30 was replaced by alanine, D-alanine and sarcosine respectively, and 3) some residues were deleted besides the above two modifications. A modified two-step deprotection / cleavage procedure, in which a solvent of TFA / TMSBr / thioanisole / EDT / m-cresol combines with HF cleavage, was adopted in SPPS.
基金supported by the National Natural Science Foundation of China(Nos.82003687,52203138)supported by the Jilin Scientific and Technological Development Program(No.20200201415JC)+1 种基金supported by the Finance Project of Jilin ProvinceChina(Nos.2019SRCJ016,2020SCZT036)。
文摘Osteoporosis is a disease of bone metabolism homeostasis imbalance with obvious bone loss,damage to bone microstructure,and increased risk of fracture.The occurrence and development of osteoporosis is related to the augmentation of active osteoclasts.Receptor activator of nuclear factor kappa B(RANK)small interfering RNA(siRNA)knockdowns the expression of RANK mRNA to inhibit the osteoclast precursors differentiate into osteoclasts as a treatment in osteoporosis.Salmon calcitonin(sCT)is a commonly used anti-osteoporotic agent that inhibits osteoclast activity and induces osteoclast apoptosis,and it also could promote the osteogenesis by osteoblasts.A cocktail therapy improves the therapeutic effect of osteoporosis between RANK siRNA and sCT.A size-switchable microsphere from micro to nano scale was developed to address the delivery barriers of biomacromolecules with poor stability and frequent administration.RANK siRNA and s CT were incorporated into the microspheres with a nanoparticle/micellemicrosphere double-layer structure to achieve sustained release when the particle size shrunk and dual protection of RANK siRNA and sCT.The size-switchable microspheres MS@(AL-NPs/ARM)had an optimal therapeutic effect and reduced the frequency of administration in glucocorticoid induced osteoporosis(GIOP)mouse model.RANK siRNA and s CT co-delivery system based on size-switchable microsphere is a promising strategy to treat osteoporosis through the controlled release of biomacromolecules.
